Anixa Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANIX research report →
Companywww.anixa.com
Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
- CEO
- Amit Kumar
- IPO
- 1983
- Employees
- 5
- HQ
- San Jose, CA, US
Price Chart
Valuation
- Market Cap
- $91.53M
- P/E
- -8.80
- P/S
- 0.00
- P/B
- 6.02
- EV/EBITDA
- -8.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -65.55%
- ROIC
- -78.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,927,000 · 12.96%
- EPS
- $-0.34 · 12.82%
- Op Income
- $-11,701,000
- FCF YoY
- 2.21%
Performance & Tape
- 52W High
- $5.46
- 52W Low
- $2.44
- 50D MA
- $2.84
- 200D MA
- $3.35
- Beta
- 0.65
- Avg Volume
- 109.38K
Get TickerSpark's AI analysis on ANIX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | Baskies Arnold M | buy | 10,000 |
| Jan 5, 26 | Titterton Lewis H jr | other | 25,000 |
| Jan 5, 26 | KUMAR AMIT | other | 350,000 |
| Jan 5, 26 | Gottschalk Emily | other | 25,000 |
| Jan 5, 26 | Catelani Michael | other | 175,000 |
| Jan 5, 26 | Baskies Arnold M | other | 25,000 |
| Dec 15, 25 | Titterton Lewis H jr | other | 16,000 |
| Dec 15, 25 | Titterton Lewis H jr | other | 16,000 |
| Oct 30, 25 | KUMAR AMIT | other | 200,000 |
| Oct 30, 25 | KUMAR AMIT | other | 169,439 |
Our ANIX Coverage
We haven't published any research on ANIX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANIX Report →